К содержанию
Dr. Tara EinullaevaMedical oncologist

Diagnosis and tests 5 min

Metastases with no primary tumour found: what to do

What “cancer of unknown primary” means, how it is investigated and treated, and why immunohistochemistry and molecular profiling matter.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 23 October 2026

Sometimes metastases are found while the primary tumour remains unclear after investigation. This is called cancer of unknown primary (CUP). The diagnosis is frightening, but there is a standard plan for this situation.

How the source is searched for

  • Pathology review with immunohistochemistry: a panel of markers helps suggest which organ the tumour came from.
  • Imaging: CT of chest, abdomen and pelvis, sometimes PET-CT and MRI of individual organs.
  • Molecular profiling (NGS): finds mutations that affect drug choice and sometimes hints at the tumour’s origin.

How it is treated

If the source can be identified, it is treated as cancer of that organ. If not, treatment is chosen from immunohistochemistry, molecular data and the location of metastases; in some cases targeted drugs and immunotherapy are used, and when the picture is unclear, broad-spectrum chemotherapy (most often platinum combinations). Subgroups with a more favourable course, treated with specific regimens, are looked for carefully.

Subgroups with a more favourable course

ESMO guidance identifies several situations where treatment is chosen as for a specific cancer, with benefit considered higher:

  • women with metastases in axillary lymph nodes: investigated and treated as breast cancer;
  • women with peritoneal involvement (carcinomatosis): an approach as for ovarian cancer;
  • men with bone metastases and a high PSA: as for prostate cancer;
  • a single metastasis: surgery or radiotherapy may be possible;
  • squamous cell metastases in neck lymph nodes: as for head and neck tumours;
  • neuroendocrine tumours: separate regimens. That is why pathology review matters: it helps not to miss such a subgroup.

What cancer of unknown primary is

This is the situation when metastases are confirmed by biopsy but, after standard work-up, the source, the primary tumour, has not been found. It is not rare: by estimates it is a few percent of all cancer diagnoses. Sometimes the primary is tiny, sometimes it regressed on its own, sometimes it is simply not visible with available methods.

The diagnosis is made not hastily “by exclusion” but after a defined set of tests. If it was made in a hurry, that is a reason to check whether everything was done.

Which tests are needed

  • Pathology review by an experienced pathologist with an extended IHC panel: it helps suggest the organ of origin.
  • CT or PET-CT of chest, abdomen and pelvis.
  • Mammography and MRI in women, testicular ultrasound and PSA in men when indicated.
  • Endoscopy for gastrointestinal symptoms.
  • Molecular profiling (NGS): it may find mutations suitable for targeted drugs, or MSI-H, and sometimes suggests the likely origin. Tests are chosen by symptoms and histology type, not “everything at once”.

How treatment is built

If a subgroup with a known source is found, it is treated as that cancer. If not, broad-spectrum chemotherapy regimens are used and, with suitable findings, targeted drugs or immunotherapy are added.

Importantly, treatment is chosen on the basis of the molecular profile, not only a “default diagnosis”. That is why a second opinion with slide review and extended testing often changes the plan. Participation in clinical trials is also discussed.

The role of the IHC panel and slide review

The main tool for finding a tumour’s origin is immunohistochemistry: a set of stains (cytokeratins CK7 and CK20, TTF-1, CDX2, GATA3, PAX8, PSA, SOX10 and others) shows which tissue the tumour resembles. Sometimes a combination of markers points to lung, gastrointestinal tract, breast or ovary.

Laboratories work at different levels, so review of slides and blocks in an expert centre with an extended panel often clarifies the diagnosis. This is one of the most productive steps and needs no new procedure: existing material is used.

Molecular profiling: what it gives

An NGS panel searches for mutations and rearrangements (EGFR, ALK, ROS1, BRAF, HER2, NTRK, RET and others) as well as MSI, TMB and PD-L1. Even if the origin remains unclear, a finding may open a targeted drug or immunotherapy that works regardless of organ. Some algorithms infer the likely tissue from methylation or gene expression profiles, but their results must be interpreted carefully.

Profiling is usually recommended before choosing a chemotherapy line: it may change the plan.

What to expect from treatment and how not to lose time

Response to treatment in this group varies widely: in some patients the disease is controlled for months and years, in others it is less predictable. The outlook depends on the subgroup, number and location of metastases, condition and molecular findings.

To avoid losing time:

  • Put all discs, pathology reports and block and slide numbers in one folder.
  • Ask at once about pathology review and NGS.
  • Find out whether your data fit one of the subgroups with known treatment.
  • Discuss participation in clinical trials.
  • Do not delay symptom care (pain, nutrition): it runs in parallel.

What to ask your doctor

  • Is immunohistochemistry enough, or is a slide review at a reference centre needed?
  • Has molecular profiling been done?
  • Are there signs of a favourable subgroup?
  • Has a tumour board discussed the case?

If the source has not been found and you want to check the plan, I can help you work through it at a consultation.

Sources

  1. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up — ESMO

Frequently asked questions

This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.